Purpose:Prescription opioid use is increasing, leading to increased addiction and mortality. Post-operative care is often patients’ first exposure to opioids, however little data exists on national prescription patterns in urology. We aimed to examine post-discharge opioid fills after urological procedures and their association with long term use.Materials and Methods:We identified patients in a private national insurance database undergoing 15 urological procedures between October 1, 2010 and September 30, 2014. Patients with an opioid fill in the preceding 6 months were excluded. Claims for opioids from 30 days before until 7 days after an operation characterized an initial prescription. Factors associated with persistent opioid use (an opioid claim 91-180 days after the operation) and chronic opioid use (≥10 refills for ≥120 days supply in the year following the operation) were analyzed using multivariable logistic regression.Results:Overall, 96,580 patients were included, and 49,391 (51%) fill...
Introduction:Robot-assisted radical prostatectomy (RARP) has become the predominant surgical modality to manage localized prostate cancer in the US. However, there are very few studies focusing on ...
Purpose: To reduce the amount of opioids prescribed at discharge after robotic surgery, we hypothesized that the majority patients do not require opioids for pain control after robotic urologic oncologic procedures. Materials and Methods: This prospective study aimed to reduce opioids prescribed at discharge after robot-assisted radical prostatectomy (RARP), robot-assisted radical nephrectomy (RARN) and robot-assisted partial nephrectomy (RAPN). Prior to 9/2018, 100% of patients were discharged on varying amounts of oxycodone (range: 75-337.5 oral morphine milligram equivalents [MME]). We implemented a standardized non-opioid analgesia pathway with escalation options (Figure 1). To assess the safety of our approach, we analyzed pain scores, telephone encounters and ED visits in our cohort. Results: Our cohort (n=170) consisted of patients undergoing RARP (n=87), RARN (n=25), RAPN (n=58) between 9/2018-1/2019. Overall, 67.7% were discharged without opioids, 24.4% with ten pills of tramadol (50 MME) and 8.2% with ten pills of oxycodone (75 MME). On multivariable analysis, older age (OR: 0.961, 95% CI: 0.923-0.995, p=0.026) was associated with lower odds of needing opioids at discharge. There was no difference in pain scores at the post-operative outpatient visit (p=0.66) or postoperative telephone encounters (p=0.45) between those discharged with and without opioids. Conclusion: The majority of robotic surgery patients do not require opioids upon discharge. Implementation of a simple, standardized, non-opioid protocol resulted in a dramatic reduction in the amount of opioids prescribed in our patient population. An escalation protocol allows for a patient centered approach to reduce narcotic prescribing while still addressing surgical pain.
PURPOSE: Self-administered oncology drugs contribute disproportionately to Medicare Part D spending; prices often remain high even after generic entry. Outlets for low-cost drugs such as Mark Cuban Cost Plus Drug Company (MCCPDC) offer opportunities for decreased Medicare, Part D, and beneficiary spending. We estimate potential savings if Part D plans obtained prices such as those offered under the MCCPDC for seven generic oncology drugs. METHODS: Using the 2020 Medicare Part D Spending dashboard, Q3-2022 Part D formulary prices, and Q3-2022 MCCPDC prices for seven self-administered generic oncology drugs, we estimated Medicare savings by replacing Q3-2022 Part D unit costs with costs under the MCCPDC plan. RESULTS: We estimate potential savings of $661.8 million (M) US dollars (USD; 78.8%) for the seven oncology drugs studied. Total savings ranged from $228.1M USD (56.1%) to $2,154.5M USD (92.4%) compared with 25th and 75th percentiles of Part D plan unit prices. The median savings replacing Part D plan prices were abiraterone $338.0M USD, anastrozole $1.2M USD, imatinib 100 mg $15.6M USD, imatinib 400 mg $212.0M USD, letrozole $1.9M USD, methotrexate $26.7M USD, raloxifene $63.8M USD, and tamoxifen $2.6M USD. All 30-day prescription drug prices offered by MCCPDC generated cost savings except for three drugs offered at the 25th percentile Part D formulary pricing: anastrozole, letrozole, and tamoxifen. CONCLUSION: Replacing current Part D median formulary prices with MCCPDC pricing could yield significant savings for seven generic oncology drugs. Individual beneficiaries could save nearly $25,200 USD per year for abiraterone or between $17,500 USD and $20,500 USD for imatinib. Notably, Part D cash-pay prices for abiraterone and imatinib under the catastrophic phase of coverage were still more expensive than baseline MCCPDC prices.